Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125380801 | 12538080 | 1 | I | 20160627 | 20160707 | 20160707 | EXP | US-TEVA-673248USA | TEVA | ALIMIN C, COX-VANCE L. TO TEST OR NOT TO TEST-THE ROLE OF GENETIC TESTING IN WARFARIN MANAGEMENT IN OLDER ADULTS. J-AM-GERIATR-SOC 2016;64 (SUPPL. S1):S154. | 79.00 | YR | F | Y | 0.00000 | 20160707 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125380801 | 12538080 | 1 | PS | WARFARIN | WARFARIN | 1 | Unknown | 4 MG DAILY | 40145 | ||||||||||
| 125380801 | 12538080 | 2 | C | ENOXAPARIN SODIUM. | ENOXAPARIN SODIUM | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125380801 | 12538080 | 1 | Deep vein thrombosis |
| 125380801 | 12538080 | 2 | Deep vein thrombosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125380801 | 12538080 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125380801 | 12538080 | Haematoma | |
| 125380801 | 12538080 | Hypotension | |
| 125380801 | 12538080 | Hypovolaemic shock | |
| 125380801 | 12538080 | Lethargy | |
| 125380801 | 12538080 | Tachycardia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |